EE437 Healthcare Resource Utilization and Costs in Patients with Multiple Myeloma Who Received 1 to 3 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and Exposed to (AND DISCONTINUED) Lenalidomide in the ...

Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.685
https://www.valueinhealthjournal.com/article/S1098-3015(22)00886-5/fulltext
Title : EE437 Healthcare Resource Utilization and Costs in Patients with Multiple Myeloma Who Received 1 to 3 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and Exposed to (AND DISCONTINUED) Lenalidomide in the ...
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00886-5&doi=10.1016/j.jval.2022.04.685
First page :
Section Title :
Open access? : No
Section Order : 10615
Categories :
Tags :
Regions :
ViH Article Tags :